Aqr Capital Management LLC Fate Therapeutics Inc Transaction History

Aqr Capital Management LLC

$71.5 Billion
Q3 2024

A detailed history of Aqr Capital Management LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Aqr Capital Management LLC holds 24,084 shares of FATE stock, worth $39,979. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,084

Previous 16,460 46.32%

Holding current value

$39,979

Previous $53,000 58.49%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $23,786 - $42,465	7,624 Added 46.32%	24,084 $84,000
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $18,379 - $39,917	-5,638 Reduced 25.51%	16,460 $53,000
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $753,878 - $1.78 Million	-212,960 Reduced 90.6%	22,098 $162,000
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $161,457 - $385,540	-97,853 Reduced 29.39%	235,058 $879,000
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $672,480 - $1.68 Million	332,911 New	332,911 $705,000
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $1.15 Million - $3.02 Million	271,399 New	271,399 $1.55 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $274,487 - $654,416	-15,438 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $338,030 - $686,770	-11,393 Reduced 42.46%	15,438 $599,000
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $444,959 - $598,426	-9,301 Reduced 25.74%	26,831 $1.57 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $118,065 - $190,694	-1,992 Reduced 5.23%	36,132 $2.14 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $287,628 - $395,708	4,277 Added 12.64%	38,124 $3.31 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $106,436 - $173,165	-1,475 Reduced 4.18%	33,847 $2.79 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $197,458 - $523,324	-5,184 Reduced 12.8%	35,322 $3.21 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $273,051 - $363,649	-8,979 Reduced 18.14%	40,506 $1.62 Million
Q2 2020 Aug 17, 2020	SELL	$20.21 - $35.23 $60,508 - $105,478	-2,994 Reduced 5.71%	49,485 $1.7 Million
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $577,031 - $1.06 Million	33,393 Added 174.96%	52,479 $1.17 Million
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $140,501 - $217,519	-10,493 Reduced 35.47%	19,086 $374,000
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $6,234 - $9,067	-403 Reduced 1.34%	29,579 $459,000
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $59,161 - $77,467	-3,790 Reduced 11.22%	29,982 $609,000
Q1 2019 May 14, 2019	SELL	$13.15 - $18.71 $66,302 - $94,335	-5,042 Reduced 12.99%	33,772 $593,000
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $96,351 - $142,513	-8,393 Reduced 17.78%	38,814 $498,000
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $138,957 - $204,491	15,170 Added 47.35%	47,207 $535,000
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $201,833 - $441,149	32,037 New	32,037 $313,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account

Aqr Capital Management LLC Fate Therapeutics Inc Transaction History